CD274 and neoplasm: The proportion of patients with an objective response was higher with nivolumab plus ipilimumab (55 [35%] of 158 patients) versus chemotherapy (31 [20%] of 157 patients) in patients with tumor cell PD‐L1 expression ≥1% (Table 2).